Last reviewed · How we verify
⁸⁹Zr-Df-IAB22M2C Infusion — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
⁸⁹Zr-Df-IAB22M2C Infusion (⁸⁹Zr-Df-IAB22M2C Infusion) — ImaginAb, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ⁸⁹Zr-Df-IAB22M2C Infusion TARGET | ⁸⁹Zr-Df-IAB22M2C Infusion | ImaginAb, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ⁸⁹Zr-Df-IAB22M2C Infusion CI watch — RSS
- ⁸⁹Zr-Df-IAB22M2C Infusion CI watch — Atom
- ⁸⁹Zr-Df-IAB22M2C Infusion CI watch — JSON
- ⁸⁹Zr-Df-IAB22M2C Infusion alone — RSS
Cite this brief
Drug Landscape (2026). ⁸⁹Zr-Df-IAB22M2C Infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/zr-df-iab22m2c-infusion. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab